Mivalsecovatein
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Mivalsecovatein
- mivalsecovatein
- Mivalsecovatein
- mivalsecovatein [INN]
- mivalsecovatein inn
- mivalsecovateina
- Mivalsecovateina
- mivalsecovateine
- Mivalsecovateine
- nvx cov2601
- nvx cov2601 35μg
- NVX-COV2601
- NVX-CoV2601 (35μg)
- NVX-CoV2601 (5μg)
- NVX-CoV2601(35μg)
- NVX-CoV2601(50μg)
- NVX-CoV2601(5μg)
- viral spike glycoprotein nvx cov2601 665 glutamine 666 glutamine 668 glutamine 968 proline 969 proline severe acute respiratory syndrome coronavirus 2 variant xbb 1 5
- Viral spike glycoprotein NVX-CoV2601 [665-glutamine,666-glutamine,668-glutamine,968-proline,969-proline] (severe acute respiratory syndrome coronavirus 2 variant XBB.1.5)
- CAS registry numbers
- 2928522-52-3
- ChEMBL ID
- CHEMBL6068266
- FDA ingredient codes (UNII)
- 9NLL7B5W2N
- First in class
- No
- Orphan designation
- No
Investigated indications
- Condition
- COVID-19
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition identifier
- MONDO_0100096
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 2
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- Component
- Sequence
- Type
- Protein
- Sequence
- QCVNLITRTQSYTNSETRGVYYPDKVERSSVLHSTQDLELPEESNVTWEHATHVSGINGTKREDNPALPENGVYFASTEKSNIIRGWIEGITLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYQKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKEGNEKNREFVEKNIDGYFKIYSKHTPINLERDLPQGESALEPLVDLPIGINITRFQTLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSETVEKGIYQTSNERVQPTESIVREPNITNLCPFHEVENATTEASVYAWNRKRISNCVADYSVINFAPFFAFKCYGVSPTKLNDLCETNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDETGCVIAWNSNKLDSKPSGNYNYLYRLERKSKLKPFERDISTEIYAGNKPNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNENENGLTGTGVITESNKKELPFQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVEQTRAGCLIGAEYVNNSYECDIPIGAGTCASYQTQTSHQRAQSVASQSTTAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYEGGENESQILPDPSKPSKRSFIEDLLENKVTLADAGFIKQYGDCLGIAARDLICAQKENGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRENGIGTQNVLYENQKLIANQENSAIGKIQDSLSSTASALGKLQDVNHNAQALNTLVKQLSSKEGAISSVLNDILSRUDEEEAEVQIDRLITGRLQSLQTYVTQQLTRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNETTAPAICHDGKAHEPREGVEVSNGTHWEVTQRNEYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVNIQKEIDRINEVAKNESLIDLQELGKYEQYIKWPWYIWLGEIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT
- Component
- Disulfide bridges
- Sequence
- 2-120 $ 115-149 $ 274-284 $ 319-344 $ 362-415 $ 374-508 $ 463-471 $ 521-573 $ 600-632 $ 645-654 $ 721-743 $ 726-732 $ 823-834 $ 1015-1026 $ 1065-1109
- Component
- Glycosylation sites (N)
- Sequence
- 45 $ 58 $ 106 $ 132 $ 148 $ 217 $ 265 $ 314 $ 326 $ 586 $ 599 $ 640 $ 692 $ 700 $ 784 $ 1057 $ 1081 $ 1117 $ 1141 $ 1156
Related records
Trials (4)
- Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine
- Phase 2/3 Heterologous Boosting Study With Different Dose Levels of Monovalent SARS-CoV-2 rS Vaccines
- Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
- Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study
In development for (1)
- COVID-19 Phase 2